-
-
- Ar-Ge Birimi
- Endüstriyel Aşı Üretimi Birimi
- Aşı ve Bağışıklama Eğitimi Birimi
- Aşı Epidemiyolojisi Birimi
- Preklinik ve Klinik Araştırmalar ve Proje Koordinasyon Birimi
- Pandemi Riski Yaratan Enfeksiyon Etkenleri Epidemiyolojisi Birimi
- Biyolojik Terör Birimi
- Deney Hayvanları Üretim/Test ve Preklinik Araştırma Birimi
- Doku Kültür Koleksiyonu Viral ve Bakteriyel Kültür Bankacılığı Birimi
- Kalite Kontrol Laboratuvarı Birimi
- Eğitim, İdari ve Mali Hizmetler Birimi
- Çevrim İçi Web Sayfası Birimi
-
-
-
- Duyurular
- Önemli Günler
- SSS
- İletişim
- Adverse Events in Following Immunization with Inactivated SARS-CoV-2 Vaccines (TURKOVAC and CoronaVac) in PCR-Positive Asymptomatic or Mildly Symptomatic Individuals Compared to PCR-Negative Recipients
- Temel Klinik Araştırma Eğitimlerinin Etkinliğinin Değerlendirilmesi
- The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac –inactivated COVID-19 vaccines
- Efficacy of Inactivated Bivalent SARS-CoV-2 Vaccines Targeting Ancestral Strain (ERAGEM), Delta, and Omicron Variants
- Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey
- Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial
- Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up
- Analysis of participant-reported adverse events following the first dose of inactivated SARS-Cov-2 vaccine (TURKOVACTM) through telephone survey in T€urkiye
- Self-Reported Allergic Adverse Events Following Inactivated SARS-CoV-2 Vaccine (TURKOVAC™) among General and High-Risk Population
- Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial